Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

High Prevalence of Iron Deficiency Among Daratumumab-Treated Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2023-184607

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Blood (2023) 142 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2023-182874

Published: 2023

Journal Articles

Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma

Jonas Paludo, MD, Nishanth Vallumsetla, MBBS, Shaji Kumar, MD, Rhett Ketterling, MD, Morie A Gertz, MD MACP, Angela Dispenzieri, MD, Martha Q Lacy, MD, Francis K Buadi, MD, David Dingli, MD, PhD, Utkarsh Painuly, MD, Nelson Leung, MD, Robert Kyle, MD MACP, S. Vincent Rajkumar, MD, Prashant Kapoor, MD

Blood (2014) 124 (21): 2059.

https://doi.org/10.1182/blood.V124.21.2059.2059

Published: 2014

Journal Articles

The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenströms Macroglobulinemia

Kasyapa S. Chitta, PhD, Aneel Paulus, MDMS, Maja Blake-Kuranz, Sharoon Akhtar, MPhil, Anne J. Novak, PhD, Stephen M. Ansell, MD PhD, Robert Kyle, MD MACP, Morie A Gertz, MD, Peter Martin, MD, Morton Coleman, MD, Sikander Ailawadhi, MD, Asher Chanan-Khan, MD

Blood (2014) 124 (21): 1689.

https://doi.org/10.1182/blood.V124.21.1689.1689

Published: 2014

Journal Articles

Progression and Outcome in Patients with Biclonal Gammopathies

Trey Carlton Mullikin, BS, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Morie A Gertz, MD, Martha Q Lacy, MD, Francis Buadi, MD, Prashant Kapoor, MD, Jerry A. Katzmann, PhD, Dirk Larson, Robert Kyle, MD MACP, Shaji Kumar, MD

Blood (2014) 124 (21): 5699.

https://doi.org/10.1182/blood.V124.21.5699.5699

Published: 2014

Journal Articles

High Sensitivity Detection of Malignant-Specific M-Proteins Using Mass Spectrometry

David L Murray, MD, PhD, John R Mills, PhD, Jerry A. Katzmann, PhD, Robert Kyle, MD MACP, Vincent Rajkumar, MD, Angela Dispenzieri, MD, David R Barnidge, PhD

Blood (2014) 124 (21): 3419.

https://doi.org/10.1182/blood.V124.21.3419.3419

Published: 2014

Journal Articles

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Muhamad Alhaj Moustafa, MD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Francis K Buadi, MD, Morie A Gertz, MD, Martha Q. Lacy, MD, Prashant Kapoor, MD, Suzanne R Hayman, MD, David Dingli, MD, PhD, Robert Kyle, MD, Shaji Kumar, MD

Blood (2014) 124 (21): 3427.

https://doi.org/10.1182/blood.V124.21.3427.3427

Published: 2014

Journal Articles

A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma

Blood (2013) 122 (21): 1940.

https://doi.org/10.1182/blood.V122.21.1940.1940

Published: 2013

Journal Articles

17p Deleted Multiple Myeloma: Clinical Outcomes and Predictive Factors For Acquisition Of 17p Deletion

Utkarsh Painuly, MD, Vincent Rajkumar, MD, Rhett P Ketterling, Angela Dispenzieri, MD, Martha Q Lacy, MD, Morie A Gertz, MD, MACP, Francis K Buadi, MD, David Dingli, M.D., Ph.D., Suzanne R Hayman, MD, Prashant Kapoor, MD, Arleigh McCurdy, MD, Nelson Leung, MD, John A Lust, MD, PhD, Stephen J. Russell, MD, PhD, Steven R Zeldenrust, MD, PhD, Yi Lin, MDPhD, Robert Kyle, MD, MACP, Shaji K Kumar, MD

Blood (2013) 122 (21): 1846.

https://doi.org/10.1182/blood.V122.21.1846.1846

Published: 2013

Journal Articles

Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma

Taxiarchis Kourelis, MD, Shaji K Kumar, MD, Geetika Srivastava, MBBS, Morie A Gertz, MD, MACP, Martha Q Lacy, MD, Francis K Buadi, MD, Suzanne R Hayman, MD, Steven R Zeldenrust, MD, PhD, Nelson Leung, MD, Robert Kyle, MD, MACP, Stephen Russell, David Dingli, M.D., Ph.D., John A Lust, MD, PhD, Yi Lin, MDPhD, Prashant Kapoor, MD, Arleigh McCurdy, MD, Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2013) 122 (21): 3209.

https://doi.org/10.1182/blood.V122.21.3209.3209

Published: 2013

Journal Articles

Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients

Lindsey E. Roeker, Dirk Larson, Robert Kyle, MD, MACP, Shaji K Kumar, MD, Angela Dispenzieri, MD, Vincent Rajkumar, MD

Blood (2013) 122 (21): 3134.

https://doi.org/10.1182/blood.V122.21.3134.3134

Published: 2013

Journal Articles

Incidence and Survival Outcomes Of Extramedullary Myeloma

Krishna B Ghimire, MD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Martha Q Lacy, MD, Morie A Gertz, MD, Francis K Buadi, MD, David Dingli, M.D., Ph.D., Suzanne R Hayman, MD, Prashant Kapoor, MD, Arleigh McCurdy, MD, Nelson Leung, MD, Stephen Russell, John A Lust, MD, PhD, Steven R Zeldenrust, MD, PhD, Yi Lin, MD, PhD, Robert Kyle, MD, MACP, Shaji K Kumar, MD

Blood (2013) 122 (21): 3141.

https://doi.org/10.1182/blood.V122.21.3141.3141

Published: 2013

Journal Articles

Survival Outcomes Of Very Young (<40 years) Myeloma Patients

Utkarsh Painuly, MD, Shivlal Pandey, MD, Shaji K Kumar, MD, Robert Kyle, MD, MACP, Martha Q Lacy, MD, Morie A Gertz, MD, MACP, Vincent Rajkumar, MD, Suzanne R Hayman, MD, Francis Buadi, MD, David Dingli, M.D., Ph.D., Stephen J. Russell, MD, PhD, John A Lust, MD, PhD, Arleigh McCurdy, MD, Angela Dispenzieri, MD, Prashant Kapoor, MD

Blood (2013) 122 (21): 2136.

https://doi.org/10.1182/blood.V122.21.2136.2136

Published: 2013

Journal Articles

Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Angela Dispenzieri, MD, Amy K. Saenger, M.D., Shaji K. Kumar, MD, Morie A. Gertz, M.D., Martha Q Lacy, MD, Francis Buadi, MD, Suzanne R Hayman, MD, Nelson Leung, MD, Steven R Zeldenrust, MD, PhD, Arleigh McCurdy, MD, Robert Kyle, MD, MACP, David Dingli, M.D., Ph.D., Prashant Kapoor, MD, Yi Lin, MDPhD, Stephen J. Russell, MD, PhD, Ronald S. Go, MD, Allan S. Jaffe, M.D.

Blood (2013) 122 (21): 3095.

https://doi.org/10.1182/blood.V122.21.3095.3095

Published: 2013

Journal Articles

Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents

Morie A Gertz, MD, MACP, Suzanne R Hayman, MD, David Dingli, M.D., Ph.D., Angela Dispenzieri, MD, Prashant Kapoor, MD, Shaji K Kumar, MD, Martha Q Lacy, MD, Nelson Leung, MD, Yi Lin, MDPhD, John A Lust, MD, PhD, Joseph R. Mikhael, MD, S. Vincent Rajkumar, MD, Stephen J. Russell, MD, PhD, Steven R Zeldenrust, MD, PhD, Robert Kyle, MD, MACP, Francis K Buadi, MD

Blood (2013) 122 (21): 3117.

https://doi.org/10.1182/blood.V122.21.3117.3117

Published: 2013

Journal Articles

Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience

Jonas Paludo, MD, Utkarsh Painuly, MD, Shaji Kumar, MD, Francis Buadi, MD, Suzanne R Hayman, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, John A. Lust, MD, PhD, David Dingli, M.D., Ph.D., Arleigh McCurdy, MD, Stephen J. Russell, MD, PhD, Nelson Leung, MD, Steven R Zeldenrust, MD, PhD, Vincent Rajkumar, MD, Morie A Gertz, M.D., Robert Kyle, MD, MACP, Prashant Kapoor, MD

Blood (2013) 122 (21): 3119.

https://doi.org/10.1182/blood.V122.21.3119.3119

Published: 2013

Journal Articles

Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials

Preet Paul Singh, MD, Shaji K Kumar, MD, Betsy R. LaPlant, Morie A Gertz, M.D., Angela Dispenzieri, MD, P. Leif Bergsagel, MD, Martha Q Lacy, MD, Siddharth Singh, MD, Vivek Roy, M.D., Francis K Buadi, MD, David Dingli, M.D., Ph.D., Robert Kyle, MD, MACP, S. Vincent Rajkumar, MD, Prashant Kapoor, MD

Blood (2013) 122 (21): 407.

https://doi.org/10.1182/blood.V122.21.407.407

Published: 2013

Journal Articles

Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience

Anita D'Souza, Martha Lacy, Morie Gertz, Shaji Kumar, Francis Buadi, Suzanne Hayman, David Dingli, Steven Zeldenrust, Robert Kyle, Stephen Ansell, David Inwards, Patrick Johnston, Ivana Micallef, Luis Porrata, Mark Litzow, Dennis Gastineau, William Hogan, Angela Dispenzieri

Blood (2012) 120 (1): 56–62.

https://doi.org/10.1182/blood-2012-04-423178

Published: 2012

Journal Articles

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

Blood (2011) 117 (18): 4696–4700.

https://doi.org/10.1182/blood-2010-10-300970

Published: 2011

NARROW

High Prevalence of Iron Deficiency Among Daratumumab-Treated Newly Diagnosed Multiple Myeloma Patients

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma

The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenströms Macroglobulinemia

Progression and Outcome in Patients with Biclonal Gammopathies

High Sensitivity Detection of Malignant-Specific M-Proteins Using Mass Spectrometry

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma

17p Deleted Multiple Myeloma: Clinical Outcomes and Predictive Factors For Acquisition Of 17p Deletion

Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma

Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients

Incidence and Survival Outcomes Of Extramedullary Myeloma

Survival Outcomes Of Very Young (<40 years) Myeloma Patients

Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents

Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience

Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials

Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only